Healthcare

Pennsylvania’s attorney general accuses insulin makers, PBMs of insulin ‘pricing scheme’

State Attorney General Dave Sunday’s office claims that more than a dozen pharmaceutical companies and pharmacy middlemen worked together to “artificially” inflate insulin prices by more than 1,000%. 

Pennsylvania AG Dave Sunday is suing another social media platform alleging harm to kids
Dave Sunday sitting before his swearing-in ceremony at the Forum Building in Harrisburg on Jan 20, 2025. (Photo: Sean Kitchen)

State Attorney General Dave Sunday’s office claims that more than a dozen pharmaceutical companies and pharmacy middlemen worked together to “artificially” inflate insulin prices by more than 1,000%. 

“Millions of Pennsylvanians have diabetes or prediabetes and they were all potentially harmed by this scheme to artificially inflate pricing to maximize company profits,” Sunday said in a release. “Our Antitrust Section will continue to hold accountable companies, large and small, that prioritize profits over public access to affordable life-saving medication and care.”

Tuesday’s lawsuit, filed in the Commonwealth Court of Pennsylvania, accuses manufacturers such as Eli Lilly and Company, Novo Nordisk, Inc. and Sanofi-Aventis US LLC of working with pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark and Optum RX to increase prices. 

PBMs operate as brokers between manufacturers, distributors and pharmacies, with a role under increasing scrutiny from lawmakers, regulators and critics — some of whom claim their existence adds to increasing drug prices. 

The three biggest PBMs, all parties to the lawsuit, manage roughly 80% of all prescription drug claims in addition to being owned by parent companies overseeing major insurance or pharmacy companies, setting up potential conflicts of interest. 

Sunday is the latest state attorney general to sue over insulin prices — a list that includes 2026 lawsuits filed in both Oregon and Florida. Earlier this year, the Federal Trade Commission announced settlement agreements with Caremark and Express Scripts after the agency accused three PBMS of driving up list prices. 

The case against the third PBM, Optum, was withdrawn to consider a proposed consent agreement, according to the agency. 

In most cases, insulin costs no more than $35 per month, but many still report rationing their medication. Without insulin or proper management, people can develop kidney failure, require amputation or die.

Sunday’s lawsuit seeks injunctive relief, changes to force lower prices and restitution for harmed Pennsylvanians.

Keep The Keystone free for everyone

If you found this story useful, would you consider supporting The Keystone?

Every day, our team works to provide Pennsylvanians with free, fact-based reporting about the issues, policies, and decisions shaping life across the commonwealth. We believe everyone deserves access to trustworthy local news—not just those who can afford a subscription.

That's why you'll never hit a paywall here (though we may ask you to sign up for our newsletter). But keeping our journalism free depends on readers who believe informed communities are worth investing in.

If our reporting has helped you better understand what's happening in Pennsylvania, please consider making a donation today. Every contribution helps us continue reporting, informing, and serving communities across the state.

Patrick Berkery
Patrick Berkery Senior Newsletter Editor
Support our team